Gene Therapy for X Linked Severe Combined Immunodeficiency

Status Recruiting

Clinical Trial Summary

A safety and efficacy clinical study of a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells in ten children with genetic diagnosed X-SCID（severe combined immune deficiency ）.The ten children will be followed for 3-5 years and be evaluated by clinical characteristics, vector marking (vector copy number per cell) in blood and bone marrow cells, immune reconstitution vector insertion-site patterns and so on.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Gene Therapy
Immunologic Deficiency Syndromes
Severe Combined Immunodeficiency
X-Linked Combined Immunodeficiency Diseases

Clinical Trial Details

NCT number	NCT04286815
Study type	Interventional
Source	Children's Hospital of Chongqing Medical University
Contact	Xiaodong Zhao, PHD
Phone	18623070626
Email	zhaoxd530@aliyun.com
Status	Recruiting
Phase	N/A
Start date	May 1, 2020
Completion date	May 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03306277` - Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1	Phase 3
Recruiting	`NCT04728841` - Gene Therapy for Chinese Hemophilia A	N/A
Recruiting	`NCT05991336` - Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
Withdrawn	`NCT04358471` - Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)	Phase 2
Recruiting	`NCT01166009` - CIBMTR Research Database
Completed	`NCT03734588` - Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors	Phase 1/Phase 2
Active, not recruiting	`NCT03311503` - Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning	Phase 1/Phase 2
Recruiting	`NCT05044845` - Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy
Completed	`NCT01024998` - Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)	Phase 1
Enrolling by invitation	`NCT05210803` - Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Active, not recruiting	`NCT03520712` - Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5	Phase 1/Phase 2